Stocks Health care GOSS
NASDAQ · Health careGossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. brought in $53.3M of revenue over the twelve months to June 30, 2026, up 32.4% from a year earlier. It posted a net loss of $125.2M. In fiscal 2025 capital spending exceeded operating cash flow by $171.3M. At June 30, 2026 it held $41.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Gossamer Bio, Inc. does
Gossamer Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GOSS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $48.5M | -$170.4M | -$0.75 | -$171.3M |
| 2024 | $114.7M | -$56.5M | -$0.25 | -$3.5M |
| 2023 | $0 | -$179.8M | -$1.18 | -$159.2M |
| 2022 | $0 | -$229.4M | -$2.71 | -$187.4M |
| 2021 | n/a | -$234M | -$3.13 | -$190.4M |
| 2020 | n/a | -$243.4M | -$3.55 | -$177.9M |
Latest SEC filings
What Gossamer Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Other event 8-K
- September 16, 2026Proxy statement DEF 14A
- September 16, 2026
- September 11, 2026
- September 9, 2026Other event 8-K
- September 3, 2026Preliminary proxy statement PRE 14A
- September 3, 2026
- August 26, 2026
- August 24, 2026Activist stake changed SCHEDULE 13D/A
- August 21, 2026
Questions about GOSS
What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GOSS.
Is Gossamer Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $125.2M on revenue of $53.3M.
How much revenue does Gossamer Bio, Inc. make?
Over the twelve months to June 30, 2026 Gossamer Bio, Inc. reported revenue of $53.3M. That is 32.4% more than a year earlier.
When did Gossamer Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
Similar companies
Follow GOSS
Get an email when Gossamer Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow GOSS: get an email when it filesWhere the numbers come from
Financial figures are the values Gossamer Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.